ImmunityBio (NASDAQ:IBRX) closed at $5.52, up 39.75% after premarket updates showed significant Anktiva revenue growth, positive trial data, and new regulatory approvals, with investors anticipating BLA plans and commercialization. Trading volume surged to 176 million shares, far exceeding the three-month average of 13 million. The S&P 500 and Nasdaq Composite each dipped 0.06%. Iovance Biotherapeutics (NASDAQ:IOVA) and Krystal Biotech (NASDAQ:KRYS) rose 6.31% and 1.07%, respectively, as interest in oncology drug developers grew.
